Financial Services
Generate Biomedicines, Inc.(GENB)
Live Price
Offline$13.87
+3.74% today
Window Change
+9.64%
Window
Feb 27, 2026 โ Jun 17, 2026
- Market Cap
- $1.62B
- Revenue Growth
- +55.9%
- EPS Growth
- -196.4%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 77 bars ยท Feb 27, 2026 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Generate Biomedicines, Inc. (GENB) is a Financial Services stock with a market cap of $1.62B and listed on NASDAQ. The stock last traded around $13.87 and up 9.6% across the available one-year price window (Feb 27, 2026 โ Jun 17, 2026). Baseline metrics include revenue growth of +55.9%, EPS growth of -196.4%, a dividend yield of 0.0%. What stands out right now is revenue +55.9%, EPS -196.4%, free cash flow -68.4% with operating margin -737.0% and ROIC -89.4%. Valuation already assumes a fairly strong business story at price/sales 50.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines GENB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+55.9% vs +3.4% peer median
Operating Margin
Below sector median
-737.0% vs +4.7% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at +55.9% and EPS is at -196.4%, with operating margin around -737.0%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 6, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Benchmark Edge
GENB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GENB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GENB Max Drawdown
-26.20%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GENB and SPY.
Company Overview
Generate Biomedicines, Inc.
NASDAQ Global Market
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development. Its product includes GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma that is intended to be dosed every six months; GB-4362, an MMAE payload neutralizer monoclonal antibody; GB-5267, A MUC16 CAR-T Cell therapy. In additional, it develops Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. Generate Biomedicines, Inc. was formerly known as Generate Biologics, Inc. and changed its name to Generate Biomedicines, Inc. in February 2020. The company was incorporated in 2018 and is based in Somerville, Massachusetts.
- Leadership
- Michael T. Nally
- IPO Date
- Feb 27, 2026
- Employees
- 312
- Street Address
- 101 South Street
- Mailing
- Somerville, MA, 02143
- Region
- Somerville, MA, US
- Reporting Currency
- USD
- Investor Line
- 1 888 469 0055
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 50.9
- Price/Book
- โ
Growth
- Revenue
- +55.9%
- EPS
- -196.4%
- Free Cash Flow
- -68.4%
Profitability
- Gross Margin
- 100.0%
- Operating Margin
- -737.0%
- Net Margin
- -637.0%
- ROE
- 38.7%
- ROIC
- -89.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 2.85
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.